video: The EGFR protein modifies the amino acid tyrosine, a process that promotes lung tumor cell proliferation. The approved drug afatinib binds to a portion of the EGFR protein (red) and inhibits this process. This material relates to a paper that appeared in the June 20, issue of Science Translational Medicine, published by AAAS. The paper, by H.P. Moll at Medical University of Vienna in Vienna, Austria; and colleagues was titled, "Afatinib restrains K-RAS-driven lung tumorigenesis." view more
Credit: biolution GmbH 2018